Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | GRN | P28799 | 1/20 | 0.45 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.45 |
| ▸ | USP1 | O94782 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | CCNK | O75909 | 4/20 | 0.40 |
| ▸ | CDK12 | Q9NYV4 | 4/20 | 0.40 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.38 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.38 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.38 |
| ▸ | CDK2 | P24941 | 1/20 | 0.38 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13699068 | 0.92 | LMNA (0.45) | LMNAKMT2AGRNSORT1USP1 | |
| SCHEMBL10130636 | 0.85 | LMNA (0.49) | LMNAKMT2AGRNSORT1USP1 | |
| SCHEMBL13514043 | 0.84 | LMNA (0.50) | LMNAKMT2AGRNSORT1USP1 | |
| SCHEMBL4183301 | 0.81 | LMNA (0.48) | LMNAKMT2AGRNSORT1KDM4E | |
| SCHEMBL4178530 | 0.80 | LMNA (0.53) | LMNAKMT2AGRNSORT1USP1 | |
| SCHEMBL13623563 | 0.79 | LMNA (0.46) | LMNAKMT2AGRNSORT1USP1 | |
| SCHEMBL17159482 | 0.77 | LMNA (0.53) | LMNAKMT2AGRNSORT1USP1 | |
| SCHEMBL1599534 | 0.77 | LMNA (0.56) | LMNAKMT2AGRNSORT1KDM4E | |
| SCHEMBL29691288 | 0.77 | LMNA (0.53) | LMNAKMT2AGRNSORT1USP1 | |
| SCHEMBL18338880 | 0.77 | LMNA (0.53) | LMNAKMT2AGRNSORT1USP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7622452-B2 | C-9 alkenylidine bridged macrolides | ENANTA PHARMACEUTICALS, INC. (US) | 2009-11-24 | — | — | US | disclosed |
| US-20080119418-A1 | C-9 ALKENYLIDINE BRIDGED MACROLIDES | ENANTA PHARMACEUTICALS, INC. | 2008-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119418-A1 | C-9 ALKENYLIDINE BRIDGED MACROLIDES | CYP2C9, CCR9, DPP9 | LMNA 1881/4885KMT2A 3068/4885GRN 3516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.